Cargando…
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
OBJECTIVE: Obesity is a growing global concern compounded by limited availability of effective treatment options. The SURMOUNT development program aims to evaluate the efficacy and safety of tirzepatide as an adjunct to lifestyle intervention compared with placebo on chronic weight management in adu...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107501/ https://www.ncbi.nlm.nih.gov/pubmed/36478180 http://dx.doi.org/10.1002/oby.23612 |
_version_ | 1785026617871958016 |
---|---|
author | le Roux, Carel W. Zhang, Shuyu Aronne, Louis J. Kushner, Robert F. Chao, Ariana M. Machineni, Sriram Dunn, Julia Chigutsa, Farai B. Ahmad, Nadia N. Bunck, Mathijs C. |
author_facet | le Roux, Carel W. Zhang, Shuyu Aronne, Louis J. Kushner, Robert F. Chao, Ariana M. Machineni, Sriram Dunn, Julia Chigutsa, Farai B. Ahmad, Nadia N. Bunck, Mathijs C. |
author_sort | le Roux, Carel W. |
collection | PubMed |
description | OBJECTIVE: Obesity is a growing global concern compounded by limited availability of effective treatment options. The SURMOUNT development program aims to evaluate the efficacy and safety of tirzepatide as an adjunct to lifestyle intervention compared with placebo on chronic weight management in adults with BMI ≥ 27 kg/m(2) with or without type 2 diabetes. METHODS: The SURMOUNT program includes four global phase 3 trials NCT04184622 (SURMOUNT‐1), NCT04657003 (SURMOUNT‐2), NCT04657016 (SURMOUNT‐3), and NCT04660643 (SURMOUNT‐4). Participants are randomized to once‐weekly subcutaneous tirzepatide versus placebo in a double‐blind manner. The primary end point in all trials is the percentage change in body weight from randomization to end of treatment. Results for the primary end point for SURMOUNT‐1 were published recently and results for the other trials are expected in 2023. RESULTS: Across trials, participants have a mean age of 44.9 to 54.2 years, are mostly female (50.7% to 69.7%), and have a mean BMI of 36.1 to 38.9. CONCLUSIONS: The extensive assessment of once‐weekly tirzepatide in the global SURMOUNT program will detail the clinical effects of this first‐in‐class glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist in chronic weight management. |
format | Online Article Text |
id | pubmed-10107501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101075012023-04-18 Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program le Roux, Carel W. Zhang, Shuyu Aronne, Louis J. Kushner, Robert F. Chao, Ariana M. Machineni, Sriram Dunn, Julia Chigutsa, Farai B. Ahmad, Nadia N. Bunck, Mathijs C. Obesity (Silver Spring) ORIGINAL ARTICLES OBJECTIVE: Obesity is a growing global concern compounded by limited availability of effective treatment options. The SURMOUNT development program aims to evaluate the efficacy and safety of tirzepatide as an adjunct to lifestyle intervention compared with placebo on chronic weight management in adults with BMI ≥ 27 kg/m(2) with or without type 2 diabetes. METHODS: The SURMOUNT program includes four global phase 3 trials NCT04184622 (SURMOUNT‐1), NCT04657003 (SURMOUNT‐2), NCT04657016 (SURMOUNT‐3), and NCT04660643 (SURMOUNT‐4). Participants are randomized to once‐weekly subcutaneous tirzepatide versus placebo in a double‐blind manner. The primary end point in all trials is the percentage change in body weight from randomization to end of treatment. Results for the primary end point for SURMOUNT‐1 were published recently and results for the other trials are expected in 2023. RESULTS: Across trials, participants have a mean age of 44.9 to 54.2 years, are mostly female (50.7% to 69.7%), and have a mean BMI of 36.1 to 38.9. CONCLUSIONS: The extensive assessment of once‐weekly tirzepatide in the global SURMOUNT program will detail the clinical effects of this first‐in‐class glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist in chronic weight management. John Wiley and Sons Inc. 2022-12-07 2023-01 /pmc/articles/PMC10107501/ /pubmed/36478180 http://dx.doi.org/10.1002/oby.23612 Text en © 2022 Eli Lilly and Company. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | ORIGINAL ARTICLES le Roux, Carel W. Zhang, Shuyu Aronne, Louis J. Kushner, Robert F. Chao, Ariana M. Machineni, Sriram Dunn, Julia Chigutsa, Farai B. Ahmad, Nadia N. Bunck, Mathijs C. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program |
title | Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program |
title_full | Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program |
title_fullStr | Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program |
title_full_unstemmed | Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program |
title_short | Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program |
title_sort | tirzepatide for the treatment of obesity: rationale and design of the surmount clinical development program |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107501/ https://www.ncbi.nlm.nih.gov/pubmed/36478180 http://dx.doi.org/10.1002/oby.23612 |
work_keys_str_mv | AT lerouxcarelw tirzepatideforthetreatmentofobesityrationaleanddesignofthesurmountclinicaldevelopmentprogram AT zhangshuyu tirzepatideforthetreatmentofobesityrationaleanddesignofthesurmountclinicaldevelopmentprogram AT aronnelouisj tirzepatideforthetreatmentofobesityrationaleanddesignofthesurmountclinicaldevelopmentprogram AT kushnerrobertf tirzepatideforthetreatmentofobesityrationaleanddesignofthesurmountclinicaldevelopmentprogram AT chaoarianam tirzepatideforthetreatmentofobesityrationaleanddesignofthesurmountclinicaldevelopmentprogram AT machinenisriram tirzepatideforthetreatmentofobesityrationaleanddesignofthesurmountclinicaldevelopmentprogram AT dunnjulia tirzepatideforthetreatmentofobesityrationaleanddesignofthesurmountclinicaldevelopmentprogram AT chigutsafaraib tirzepatideforthetreatmentofobesityrationaleanddesignofthesurmountclinicaldevelopmentprogram AT ahmadnadian tirzepatideforthetreatmentofobesityrationaleanddesignofthesurmountclinicaldevelopmentprogram AT bunckmathijsc tirzepatideforthetreatmentofobesityrationaleanddesignofthesurmountclinicaldevelopmentprogram |